Provided by Tiger Trade Technology Pte. Ltd.

PolyPid Ltd.

4.28
-0.0400-0.93%
Post-market: 4.280.00000.00%16:10 EDT
Volume:51.33K
Turnover:223.93K
Market Cap:81.68M
PE:-2.05
High:4.47
Open:4.36
Low:4.25
Close:4.32
52wk High:5.12
52wk Low:2.30
Shares:19.08M
Float Shares:10.25M
Volume Ratio:1.07
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0900
EPS(LYR):-2.0900
ROE:-366.29%
ROA:-86.71%
PB:7.44
PE(LYR):-2.05

Loading ...

PolyPid posts FY2025 net loss of USD 8.47 million

Reuters
·
Feb 11

PolyPid Q4 EPS $(0.41) Misses $(0.34) Estimate.

Benzinga
·
Feb 11

PolyPid Q4 EPS USD -0.41

THOMSON REUTERS
·
Feb 11

Press Release: PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Dow Jones
·
Feb 11

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 11

PolyPid Ltd. Held Extraordinary General Meeting of Shareholders

Reuters
·
Feb 05

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

GlobeNewswire
·
Jan 28

PolyPid Ltd. Shareholders to Vote on Compensation Terms for Board Chairman at Upcoming Extraordinary Meeting

Reuters
·
Jan 01

Press Release: PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Dow Jones
·
Dec 16, 2025

BRIEF-Polypid Announces Positive FDA Pre-NDA Meeting Minutes

Reuters
·
Dec 03, 2025

PolyPid Ltd - FDA Agreed to a Rolling Nda Review, Allowing PolyPid to Submit First Completed Sections in Early 2026

THOMSON REUTERS
·
Dec 03, 2025

PolyPid Announces Positive FDA Pre-Nda Meeting Minutes for D-Plex₁₀₀ Supporting Nda Submission

THOMSON REUTERS
·
Dec 03, 2025

PolyPid Expands Share Offering to Strengthen Financial Position

TIPRANKS
·
Nov 27, 2025

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

GlobeNewswire
·
Nov 25, 2025

PolyPid Is Maintained at Buy by Roth Capital

Dow Jones
·
Nov 14, 2025

Roth MKM Remains a Buy on PolyPid (PYPD)

TIPRANKS
·
Nov 13, 2025

PolyPid price target lowered to $9 from $10 at Roth Capital

TIPRANKS
·
Nov 13, 2025

PolyPid’s Promising Future: Buy Rating Backed by D-PLEX100 Progress and Expanding Drug Delivery Pipeline

TIPRANKS
·
Nov 13, 2025

Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln

Reuters
·
Nov 12, 2025

PolyPid reports Q3 EPS (37c), consensus (52c)

TIPRANKS
·
Nov 12, 2025